Nuvation Bio Inc.
For the period ended Mar 31, 2026. Filed May 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 4, 2026
NUVB$4.20-3.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders' Equity
(Unaudited, in thousands, except share data)
For the Three Months Ended March 31, 2026 and 2025
| Common Stock andAdditional Paid-in Capital · Accumulated · AccumulatedOtherComprehensive · TotalStockholders' | ||||||
|---|---|---|---|---|---|---|
| Class A Shares | Class B Shares | Amount | Deficit | Loss | Equity | |
| Balance, December 31, 2025 | 345,503,675 | 1,000,000 | $1,421,273 | $(1,115,370) | $(187) | $305,716 |
| Exercise of stock options | 1,177,041 | — | 908 | — | — | 908 |
| Issuance of Common Stock for RSUs vested | 12,615 | — | — | — | — | — |
| Stock-based compensation | — | — | 9,033 | — | — | 9,033 |
| Net income | — | — | — | 5,397 | — | 5,397 |
| Currency translation adjustment | — | — | — | — | (268) | (268) |
| Other comprehensive loss | — | — | — | — | (1,222) | (1,222) |
| Balance, March 31, 2026 | 346,693,331 | 1,000,000 | $1,431,214 | $(1,109,973) | $(1,677) | $319,564 |
| Common Stock andAdditional Paid-in Capital · Accumulated · AccumulatedOtherComprehensive · TotalStockholders' | ||||||
|---|---|---|---|---|---|---|
| Class A Shares | Class B Shares | Amount | Deficit | Income | Equity | |
| Balance, December 31, 2024 | 336,837,872 | 1,000,000 | $1,373,958 | $(910,743) | $573 | $463,788 |
| Exercise of stock options | 1,976,775 | — | 1,082 | — | — | 1,082 |
| Issuance of Common Stock for RSUs vested | 25,778 | — | — | — | — | — |
| Stock-based compensation | — | — | 7,854 | — | — | 7,854 |
| Net loss | — | — | — | (53,236) | — | (53,236) |
| Currency translation adjustment | — | — | — | — | 465 | 465 |
| Other comprehensive loss | — | — | — | — | (493) | (493) |
| Balance, March 31, 2025 | 338,840,425 | 1,000,000 | $1,382,894 | $(963,979) | $545 | $419,460 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.